The Readout Loud

The Readout Loud

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Tämä podcast on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi podcastin jaksot saattavat sisältää mainontaa.

Jaksot(417)

404: What RevMed's pancreatic cancer drug meant for one patient

404: What RevMed's pancreatic cancer drug meant for one patient

Why did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete be...

4 Kesä 37min

403: Biotech exec Jeremy Levin on the industry's strategic turning point

403: Biotech exec Jeremy Levin on the industry's strategic turning point

On this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust.” That...

28 Touko 47min

402: Guarding biotech from China and big bets in longevity

402: Guarding biotech from China and big bets in longevity

On this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share some of the juicy conv...

21 Touko 44min

401: Makary’s departure and Cassidy’s tenuous Senate seat

401: Makary’s departure and Cassidy’s tenuous Senate seat

This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his policies will stick, an...

14 Touko 40min

400:  Seaport's IPO adventure, obesity pill battles, and Makary's troubles

400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles

On this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat about this week’s notab...

7 Touko 33min

399: Hair-raising trial results, and Servier’s M&A wishlist

399: Hair-raising trial results, and Servier’s M&A wishlist

Why are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A arena? We get into all...

30 Huhti 41min

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts

How did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a telehealth company called Presc...

23 Huhti 37min

397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment

On this week’s episode of the Readout LOUD: a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma. Your favorite biotech podcasting crew is back to full stren...

16 Huhti 49min

Suosittua kategoriassa Liike-elämä ja talous

sijotuskasti
vallattomat
psykopodiaa-podcast
mimmit-sijoittaa
rss-rahapodi
rss-rahamania
ostan-asuntoja-podcast
rss-oivalluksia-rahasta-elamasta
lakicast
hyva-paha-johtaminen
rss-sami-miettinen-neuvottelija
rss-paasipodi
rss-pinnan-alle
oppimisen-psykologia
pomojen-suusta
rss-karon-grilli
rss-yritys-ja-erehdys
rss-lentopaivakirjat
leadcast
rss-asuntosalkku-kasvussa-podcast